$UZX

Linkage Global Inc. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

Linkage Global Inc. (NASDAQ: UZX) said Nasdaq notified it on June 3, 2026 that its Class A ordinary shares failed the $1 minimum bid price requirement for 30 straight business days, under Nasdaq Rule 5550(a)(2). The notice has no immediate trading impact. The company has 180 days, until Nov. 30, 2026, to regain compliance, with a possible 180-day extension via reverse split if eligible.

Original reporting
Published Jun 5, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Linkage Global Inc. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement — source image
Decision brief

The 30-second read

$UZXBearishMed
01

Why it matters

UZX now faces a defined path to regain compliance (potentially including a reverse stock split) or face delisting notice if it cannot cure deficiency or meet other continued listing standards.

02

Market read

This is a concrete listing-compliance catalyst that can drive valuation compression and higher volatility for UZX until compliance is restored or delisting risk becomes imminent.

03

What to watch

Traders should monitor whether UZX’s bid price can recover organically (liquidity/volume, financing, market-making) versus relying solely on a reverse split.

Relevance 9/10Novelty 9/10Timing: Immediately after-hours/next-session positioning around delisting overhang and cure-period expectations

Background

Nasdaq Listing Rule 5550(a)(2) requires a minimum $1 bid price; failure for 30 consecutive business days triggers a compliance notification and a cure period.

Company-level read

Ticker impact

$UZXBearishHigh confidence
Context

Nasdaq notified Linkage Global that UZX failed the $1 minimum bid price rule for 30 straight days, triggering a 180-day cure period.

Expected impact

Near-term downside bias from delisting overhang; volatility likely increases around compliance milestones and any reverse-split signaling.

Evidence & confidence

The article is a direct Nasdaq compliance notice tied to the continued listing rule and provides explicit cure timelines and possible reverse-split eligibility.

Market effects

Reinforces ongoing Nasdaq bid-price compliance pressure for micro/small-cap issuers, potentially increasing sector-wide volatility and reverse-split chatter.

Limited direct regional spillover; primarily affects US-listed small-cap sentiment despite Tokyo HQ.

Low; this is company-specific listing compliance rather than a cross-market macro shock.

Counterpoint

Because the notice has no immediate effect on trading and provides a long compliance window, the market may over-discount delisting risk.

Key entities

  • Linkage Global Inc.

    Nasdaq-listed issuer (UZX) that received the minimum bid price deficiency notice.

  • Nasdaq Listing Qualifications Department

    The Nasdaq unit that issued the notification letter based on the last 30 business days’ closing bid price.

Related articles

$UZXMedAI 9/10

Linkage Global Inc. Announces $8 Million Share Repurchase Program

Linkage Global Inc. (NASDAQ: UZX) said its management approved an $8 million share repurchase program for Class A ordinary shares. The company plans to buy shares from time to time via open-market or other permitted transactions, funded by existing cash and future cash flow. Timing and size will depend on capital needs and market conditions.

$AVGOMed

Why Broadcom Stock Inched Higher on Friday

Broadcom (AVGO) stock rose 1.2% on Friday, outperforming the S&P 500, after BMO Capital Markets initiated coverage with an outperform rating and a $455 price target. Analyst Harsh Kumar ranked Broadcom second in the semiconductor sector, citing the growing AI trend. J.P. Morgan's Nikolaos Panigirtzoglou also noted AI-related revenue supporting capital expenditures.

$AMLXHighAI 9/10

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Amylyx Pharmaceuticals' stock surged nearly 79% after positive Phase 3 trial results for avexitide, a drug targeting post-bariatric hypoglycemia. The company also announced a $500 million secondary stock offering. Analysts raised price targets, with Guggenheim's Seamus Fernandez setting a new target of $55 per share. The stock closed at $38.66, giving the company a market cap of $4.4 billion.

$CRMLHigh

Why Did Critical Metals Stock Just Gain 22.6%?

Critical Metals (CRML) rose 22.6% after its CEO confirmed the Tanbreez project in Greenland is on track for rare-earth production within three years. The company also detailed its acquisition of European Lithium, increasing its stake to 100%. The U.S. government has shown interest in rare-earth mining, but CRML is pre-revenue and faces a long timeline to production.

$AMLXMed

Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?

Amylyx Pharmaceuticals (AMLX) released Phase 3 LUCIDITY trial results for avexitide, a treatment for post-bariatric hypoglycemia. Shares rose 15.7% after-hours. The trial's success could validate Amylyx's shift to endocrine disease, while failure may refocus attention on earlier-stage programs. The company has $250.8M in cash, sufficient until 2028. Avexitide has Breakthrough Therapy designation, with a potential 2027 launch if approved.

$NSCMedAI 8/10

Do Wall Street Analysts Like Norfolk Southern Stock?

Norfolk Southern (NSC) stock has risen 21% over the past year, outperforming the S&P 500 and its industry ETF. Analysts expect 1.4% EPS growth for 2023, with a 'Moderate Buy' consensus. Wells Fargo set a $385 price target, implying a 5.1% upside. The company gained 2% after regulatory approval for a coast-to-coast freight network with Union Pacific.